AJP - Endo Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 289: E46-E52, 2005. First published February 15, 2005; doi:10.1152/ajpendo.00583.2004
0193-1849/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/1/E46    most recent
00583.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DiCostanzo, C. A.
Right arrow Articles by Cherrington, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DiCostanzo, C. A.
Right arrow Articles by Cherrington, A. D.

Simulated first-phase insulin release using Humulin or insulin analog HIM2 is associated with prolonged improvement in postprandial glycemia

Catherine A. DiCostanzo,1 Mary Courtney Moore,1 Margaret Lautz,1 Melanie Scott,1 Ben Farmer,1 Carrie A. Everett,1 J. Gordon Still,2 Alan Higgins,2 and Alan D. Cherrington1

1Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee; and 2Nobex Corporation, Research Triangle Park, North Carolina

Submitted 10 December 2004 ; accepted in final form 9 February 2005

We examined the extent to which priming the liver with a pulse of Humulin or the insulin analog hexyl-insulin monoconjugate 2 (HIM2) reduces postprandial hyperglycemia. Somatostatin (0.5 µg·kg–1·min–1) was given with basal intraportal insulin and glucagon for 4.5 h into three groups of 42-h-fasted conscious dogs. From 0–5 min, group 1 (BI, n = 6) received saline, group 2 (HI, n = 6) received a Humulin pulse (10 mU·kg–1·min–1), and group 3 (HIM2, n = 6) received a HIM2 pulse (10 mU·kg–1·min–1). Duodenal glucose was infused (5.0 mg·kg–1·min–1) from 15 to 270 min. Arterial insulin in BI remained basal (6 ± 1 µU/ml) and peaked at 52 ± 15 (HI) and 164 ± 44 µU/ml (HIM2) and returned to baseline by 30 and 60 min, respectively. Arterial plasma glucose plateaued at 265 ± 20, 214 ± 15, and 193 ± 14 mg/dl in BI, HI, and HIM2. Glucose absorption was similar in all groups. Significant net hepatic glucose uptake occurred at 85, 55, and 25 min in BI, HI, and HIM2, respectively. Nonhepatic glucose clearance at 270 min differed among groups (BI, HI, HIM2): 0.62 ± 0.11, 0.76 ± 0.26, and 1.61 ± 0.29 ml·kg–1·min–1 (P < 0.05). A brief (5-min) insulin pulse improved postprandial glycemia, stimulating hepatic glucose uptake and prolonging enhancement of nonhepatic glucose clearance. HIM2 was more effective than Humulin, perhaps because its lowered clearance caused higher levels at the liver and periphery and its biological activity was not reduced proportionally to its decreased clearance.

hexyl-insulin monoconjugate 2; insulin action



Address for reprint requests and other correspondence: C. DiCostanzo, 710 Medical Research Bldg. I, Vanderbilt Univ. Medical School, Nashville, TN 37232-0615 (e-mail: Catherine.dicostanzo{at}vanderbilt.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.